HIV Treatment Guidelines Give Kaletra Timely Boost As Reyataz Launches
Executive Summary
HHS' revised guidelines for HIV treatment give Abbott's Kaletra a timely endorsement as Bristol-Myers Squibb is launching its competing protease inhibitor Reyataz